Sema Cetinkaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sema Cetinkaya has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ayse Kocak
Department of Medical Biochemistry, Kütahya Health Sciences University, Kütahya, Türkiye
1 shared publication - Birkan Açikgoz
Department of Engineering Basic Sciences, Faculty of Engineering and Natural Sciences, Kutahya Health Sciences University, Kutahya, Türkiye
1 shared publication - Elif Aydin
Vocational School of Health Services, Kütahya Health Sciences University, Kütahya, Turkey
1 shared publication - Güllü Kaymak
Department of Medical Services and Techniques, Kütahya Health Sciences University, Kütahya, Türkiye
1 shared publication - Meliha Koldemir Gündüz
Department of Basic Engineering Sciences, Kütahya Health Sciences University, Kütahya, Türkiye
1 shared publication - Sercan Simsek
Department of Medical Pathology, Kutahya Evliya Celebi Education and Research Hospital, Kutahya, Türkiye
1 shared publication
Latest Publications
- 5 December 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 164
Antibacterial and immuno-oxidative effects of Melittin against Helicobacter pylori: in vitro and in vivo evidence
Helicobacter pylori (H. pylori) is a common pathogen that causes serious pathologies such as gastritis, ulcers, and gastric cancer. This study evaluates the therapeutic effects of melittin on H. pylori induced gastric injury, oxidative stress, and tissue damage in an in vivo model. Melittin was administered at two doses (10 µg/kg and 40 µg/kg) and outcomes were compared with standard antibiotic therapy. H. pylori infection significantly increased gastric urease activity, the pro-inflammatory cytokine IL-1β, and oxidative stress markers total oxidant status (TOS) and malondialdehyde (MDA); these increases were suppressed by melittin treatment. Melittin also enhanced antioxidant capacity total antioxidant status (TAS) and glutathione (GSH) and supported gastric tissue healing by reducing inflammation and neutrophil activity. Notably, 10 µg/kg melittin led to a ~ 74% reduction in bacterial colony counts and decreased tissue damage. Histopathology confirmed that melittin lowered H. pylori colonization and inflammation scores. Furthermore, the higher dose (40 µg/kg) showed more limited effects on oxidative stress than the lower dose. GSH levels improved with melittin. Melittin demonstrates antibacterial and anti-inflammatory activity against H. pylori associated gastric pathology, with several outcomes favoring the lower dose (10 µg/kg). These findings indicate melittin as a promising therapeutic candidate; however, additional comprehensive studies are needed to support clinical translation.
- 5 December 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 164
Antibacterial and immuno-oxidative effects of Melittin against Helicobacter pylori: in vitro and in vivo evidence
Helicobacter pylori (H. pylori) is a common pathogen that causes serious pathologies such as gastritis, ulcers, and gastric cancer. This study evaluates the therapeutic effects of melittin on H. pylori induced gastric injury, oxidative stress, and tissue damage in an in vivo model. Melittin was administered at two doses (10 µg/kg and 40 µg/kg) and outcomes were compared with standard antibiotic therapy. H. pylori infection significantly increased gastric urease activity, the pro-inflammatory cytokine IL-1β, and oxidative stress markers total oxidant status (TOS) and malondialdehyde (MDA); these increases were suppressed by melittin treatment. Melittin also enhanced antioxidant capacity total antioxidant status (TAS) and glutathione (GSH) and supported gastric tissue healing by reducing inflammation and neutrophil activity. Notably, 10 µg/kg melittin led to a ~ 74% reduction in bacterial colony counts and decreased tissue damage. Histopathology confirmed that melittin lowered H. pylori colonization and inflammation scores. Furthermore, the higher dose (40 µg/kg) showed more limited effects on oxidative stress than the lower dose. GSH levels improved with melittin. Melittin demonstrates antibacterial and anti-inflammatory activity against H. pylori associated gastric pathology, with several outcomes favoring the lower dose (10 µg/kg). These findings indicate melittin as a promising therapeutic candidate; however, additional comprehensive studies are needed to support clinical translation.